MCID: VRL005
MIFTS: 52

Viral Pneumonia

Categories: Blood diseases, Infectious diseases, Respiratory diseases

Aliases & Classifications for Viral Pneumonia

MalaCards integrated aliases for Viral Pneumonia:

Name: Viral Pneumonia 12 15 17
Pneumonia, Viral 44 70

Classifications:



External Ids:

Disease Ontology 12 DOID:10533
ICD9CM 34 480
MeSH 44 D011024
SNOMED-CT 67 195880002
ICD10 32 J12 J12.9
UMLS 70 C0032310

Summaries for Viral Pneumonia

Disease Ontology : 12 A pneumonia described as an inflammatory illness of the lung commonly caused by viruses such as influenza virus, parainfluenza, adenovirus, rhinovirus, herpes simplex virus, respiratory syncytial virus, hantavirus, and cytomegalovirus.

MalaCards based summary : Viral Pneumonia, also known as pneumonia, viral, is related to middle east respiratory syndrome and pneumonia. An important gene associated with Viral Pneumonia is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Oseltamivir and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and heart, and related phenotypes are hematopoietic system and digestive/alimentary

Wikipedia : 73 Viral pneumonia is a pneumonia caused by a virus. Pneumonia is an infection that causes inflammation in... more...

Related Diseases for Viral Pneumonia

Diseases in the Pneumonia family:

Viral Pneumonia Bacterial Pneumonia

Diseases related to Viral Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 819)
# Related Disease Score Top Affiliating Genes
1 middle east respiratory syndrome 30.7 IFNB1 CXCL10 ACE2
2 pneumonia 30.5 TNF SFTPD IL6 IL17A IL10 CXCL8
3 measles 30.2 TNF IL6 IFNB1 DDX58
4 haemophilus influenzae 30.2 TNF CXCL8
5 covid-19 30.2 TNF IL6 IFNB1 CXCL8 CXCL10 ACE2
6 adult respiratory distress syndrome 30.1 TNF SFTPD IL6 IL10 CXCL8
7 mucormycosis 30.1 CRP CD4 CCR6
8 synovitis 29.9 TNF IL6 CXCL8 CRP
9 graft-versus-host disease 29.9 TNF IL6 IL10
10 toxic shock syndrome 29.9 TNF IL6 IL10 CXCL8 CRP
11 myocarditis 29.8 TNF IL6 IL17A IL10
12 disseminated intravascular coagulation 29.8 TNF IL6 IL10 CRP
13 acute myocarditis 29.7 TNF IL10 CRP CD4
14 pulmonary edema 29.6 TNF IL10 CXCL8 CRP
15 influenza 29.6 TNF IL6 IFNB1 IFITM3 DDX58 CXCL10
16 vascular disease 29.6 TNF IL6 IL10 CRP CD4 ACE2
17 acute interstitial pneumonia 29.5 SFTPD CRP CD8A CD4
18 variola major 29.4 CD8A CD4
19 avian influenza 29.4 TNF SFTPD IL6 DDX58 CXCL8 CXCL10
20 chlamydia 29.4 TNF IL6 IL17A IL10 CXCL8 CRP
21 pharyngitis 29.4 TNF IL6 CXCL8 CRP CD8A CD4
22 chickenpox 29.3 TNF IL6 IL10 IFNB1 CRP CD8A
23 rhinitis 29.2 TNF IL6 IL17A IL10 CXCL8 CCL5
24 mycoplasma pneumoniae pneumonia 29.2 TNF SFTPD IL6 IL17A IL10 CRP
25 pulmonary alveolar proteinosis 29.2 TNF SFTPD IL6 IL10 CXCL8
26 eosinophilic pneumonia 29.2 SFTPD CXCL8 CCL5
27 bacterial infectious disease 29.1 TNF IL6 IL17A IL10 IFNB1 CXCL8
28 bronchopneumonia 29.1 TNF IL6 IL17A IL10 CXCL8 CRP
29 leukemia, chronic lymphocytic 29.0 TNF IL6 IL10 CR1 CD8A CD4
30 exanthem 29.0 TNF IL6 IL10 CXCL8 CRP CD8A
31 cryptogenic organizing pneumonia 29.0 TNF SFTPD CXCL8 CRP CD8A CD4
32 bacterial pneumonia 29.0 TNF SFTPD IL6 IL17A IL10 CXCL8
33 severe acute respiratory syndrome 28.8 TNF IL6 IL10 IFNB1 DDX58 CXCL8
34 encephalitis 28.7 TNF IL6 IL10 IFNB1 DDX58 CXCL10
35 bronchitis 28.6 TNF IL6 IL10 CXCL8 CXCL10 CRP
36 bronchiolitis 28.5 TNF SFTPD IL6 IL17A IL10 CXCL8
37 disease by infectious agent 28.4 TNF SFTPD IL6 IL17A IL10 IFNB1
38 aspergillosis 28.3 TNF SFTPD IL6 IL10 CXCL8 CXCL10
39 sarcoidosis 1 28.2 TNF SFTPD CXCL10 CRP CD8A CD4
40 interstitial lung disease 28.2 TNF SFTPD IL6 IL17A IL10 CXCL8
41 lung disease 28.1 TNF SFTPD NSMCE3 IL6 IL17A IL10
42 respiratory failure 28.1 TNF SFTPD IL6 IL10 CXCL8 CXCL10
43 connective tissue disease 28.1 TNF SFTPD IL6 IL17A IL10 CXCL8
44 immune deficiency disease 28.0 TNF IL6 IL17A IL10 IFNB1 CXCL10
45 heart disease 27.7 TNF IL6 IL17A IL10 IFNB1 CXCL8
46 coronavirus infectious disease 27.7 TNF IL6 IL10 IFNB1 DDX58 CXCL8
47 body mass index quantitative trait locus 11 27.7 TNF SFTPD IL6 IL17A IL10 CXCL8
48 pulmonary disease, chronic obstructive 27.2 TNF SFTPD IL6 IL17A IL10 CXCL8
49 malaria 27.1 TNF IL6 IL17A IL10 IFNB1 CXCL8
50 lung disease, immunodeficiency, and chromosome breakage syndrome 11.0

Comorbidity relations with Viral Pneumonia via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypothyroidism
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Viral Pneumonia:



Diseases related to Viral Pneumonia

Symptoms & Phenotypes for Viral Pneumonia

MGI Mouse Phenotypes related to Viral Pneumonia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ACE2 CCL5 CCR6 CD4 CD8A CXCL10
2 digestive/alimentary MP:0005381 9.86 ACE2 CD4 DDX58 IL10 IL17A IL6
3 immune system MP:0005387 9.86 ACE2 CCL5 CCR6 CD4 CD8A CRP
4 no phenotypic analysis MP:0003012 9.17 CD4 IFITM3 IFNB1 IL10 IL17A NR2F2

Drugs & Therapeutics for Viral Pneumonia

Drugs for Viral Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 171)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Acyclovir Approved Phase 4 59277-89-3 2022
3
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
7
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9 Anti-Bacterial Agents Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Anti-Infective Agents Phase 4
12 Ganciclovir triphosphate Phase 4
13 Neurotransmitter Agents Phase 4
14 Psychotropic Drugs Phase 4
15 Quetiapine Fumarate Phase 4 111974-72-2
16 Anticonvulsants Phase 4
17 Antidepressive Agents Phase 4
18 Antipsychotic Agents Phase 4
19
Mefloquine Approved, Investigational Phase 2, Phase 3 53230-10-7 4046
20
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
21
Spironolactone Approved Phase 3 1952-01-7, 52-01-7 5833
22
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
23
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
24
Cyproheptadine Approved Phase 3 129-03-3 2913
25
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
26
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
27
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
28
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
29
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
30
Dalteparin Approved Phase 3 9005-49-6
31
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
32
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
33
Enoxaparin Approved Phase 3 9005-49-6 772
34
Hydroxychloroquine Approved Phase 3 118-42-3 3652
35
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
36
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
37
Azithromycin Approved Phase 2, Phase 3 83905-01-5 55185 447043
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
40
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
41 silymarin Phase 3
42 Diuretics, Potassium Sparing Phase 3
43 Mineralocorticoids Phase 3
44 Mineralocorticoid Receptor Antagonists Phase 3
45 diuretics Phase 3
46 Immunologic Factors Phase 3
47 Immunosuppressive Agents Phase 3
48 Anti-Allergic Agents Phase 3
49 Histamine Antagonists Phase 3
50 Dermatologic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Individualizing Duration of Antibiotic Therapy in Hospitalized Patients With Community - Acquired Pneumonia: a Non-inferiority, Randomized, Controlled Trial. Unknown status NCT01492387 Phase 4
2 Title: Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia During the Influenza Season (U18) Completed NCT01248715 Phase 4 oseltamivir
3 Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial Active, not recruiting NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
4 INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia Enrolling by invitation NCT04723563 Phase 4 Heparin;0.9%sodium chloride
5 A Practical, Pilot, Randomized, Controlled Trial of Valproate Alone or in Combination With Quetiapine for Severe COVID-19 Pneumonia With Agitated Delirium Not yet recruiting NCT04513314 Phase 4 Valproate;Quetiapine
6 An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC "Farmzashita" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19 Completed NCT04347031 Phase 2, Phase 3 Mefloquine;Hydroxychloroquine
7 Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients Completed NCT04321278 Phase 3 Hydroxychloroquine + azithromycin;Hydroxychloroquine
8 Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial Completed NCT01868113 Phase 3 Inhaled corticosteroid
9 Trial of Silymarin in Adults With COVID-19 Pneumonia Recruiting NCT04394208 Phase 3 Silymarin;Placebo
10 Spironolactone and Dexamethasone in Patients Hospitalized With Moderate-to-severe COVID-19 (SPIDEX-II): a Randomized Clinical Trial Recruiting NCT04826822 Phase 3 Spironolactone + Dexamethasone;Standard-of-care SARS-CoV-2 treatment
11 Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Recruiting NCT04629703 Phase 3 Fostamatinib;Placebo
12 Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial Recruiting NCT04345289 Phase 3
13 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome Active, not recruiting NCT04369469 Phase 3
14 Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial Not yet recruiting NCT04820751 Phase 3 Cyproheptadine Hydrochloride 4 MG
15 Randomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical Ventilation Not yet recruiting NCT04408235 Phase 3 Enoxaparin
16 Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design Not yet recruiting NCT04528888 Phase 3 Enoxaparin;Methylprednisolone;unfractionated heparin
17 Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial) Not yet recruiting NCT04636671 Phase 3 Methylprednisolone;Dexamethasone
18 A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease. Terminated NCT04329611 Phase 3 Hydroxychloroquine
19 Phase III Study of Hydrocortisone in Patients With Severe H1N1 Related Pneumonia Terminated NCT01014364 Phase 3 hydrocortisone;isotonic saline
20 COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III) Terminated NCT04327401 Phase 3 Dexamethasone
21 Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia Terminated NCT04345861 Phase 2, Phase 3 Hydroxychloroquine + placebo;hydroxychloroquine + azithromycin
22 A Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP, an Alpha-1 Antitrypsin Infusion Therapy With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection Withdrawn NCT04675086 Phase 3 alpha1-proteinase inhibitor;Antiviral Agents
23 Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol Completed NCT04368377 Phase 2 Tirofiban Injection;Clopidogrel;Acetylsalicylic acid;Fondaparinux
24 A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia Completed NCT04550325 Phase 1, Phase 2
25 Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial Completed NCT04561219 Phase 2 Nitazoxanide;Placebo
26 Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia Recruiting NCT04724538 Phase 1, Phase 2 99mTc-pertechnetate aerosol
27 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, Tolerability, Biomarkers and Pharmacokinetics of Ibudilast (MN-166) in COVID-19 Subjects at Risk for Developing Acute Respiratory Distress Syndrome Recruiting NCT04429555 Phase 2 Ibudilast;Placebo
28 Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection Recruiting NCT04269525 Phase 2
29 Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial Recruiting NCT04344951 Phase 2 UNIKINON (Chloroquine phosphate) 200mg tablets
30 Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia Recruiting NCT04322565 Phase 2 Colchicine
31 A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-75 Years in Vietnam Recruiting NCT04830800 Phase 1, Phase 2
32 Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS) Recruiting NCT04331613 Phase 1, Phase 2
33 Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19 Recruiting NCT04380376 Phase 2 Melphalan
34 A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand Recruiting NCT04764422 Phase 1, Phase 2
35 Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Recruiting NCT04381364 Phase 2 Ciclesonide Inhalation Aerosol
36 Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora Recruiting NCT04366089 Phase 2 Azithromycin;hydroxychloroquine
37 A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia Recruiting NCT04335305 Phase 2 Tocilizumab
38 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 Recruiting NCT04365101 Phase 1, Phase 2
39 Randomized Controlled Phase II Trial of Poractant Alfa (Curosurf®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia Recruiting NCT04384731 Phase 2 poractant alfa
40 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial Active, not recruiting NCT04305457 Phase 2 Nitric Oxide
41 A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients Active, not recruiting NCT04476992 Phase 1, Phase 2 Nitric Oxide-Sessions;Nitric Oxide-Continuous and Sessions
42 Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Enrolling by invitation NCT04382547 Phase 1, Phase 2
43 A Randomized, Double Blind, Placebo-controlled Trial of Mavrilimumab for Acute Respiratory Failure Due to COVID-19 Pneumonia With Hyper-inflammation (the COMBAT-19 Trial) Not yet recruiting NCT04397497 Phase 2 Mavrilimumab;Placebo
44 COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 Not yet recruiting NCT04356508 Phase 2 Nivolumab
45 Extracellular Vesicle Infusion Treatment for Severe COVID-19 Not yet recruiting NCT04493242 Phase 2
46 Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection Terminated NCT04344288 Phase 2 Prednisone
47 Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial Terminated NCT04264533 Phase 2 VC;Sterile Water for Injection
48 Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 Withdrawn NCT04456088 Phase 2
49 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial Withdrawn NCT04290858 Phase 2 Nitric Oxide
50 A Retrospective Study of the Effect of Antiviral Drugs on the Treatment of SARS-CoV-2 COVID19 Recruiting NCT04727775 Phase 1 Favipiravir;Remdesivir

Search NIH Clinical Center for Viral Pneumonia

Cochrane evidence based reviews: pneumonia, viral

Genetic Tests for Viral Pneumonia

Anatomical Context for Viral Pneumonia

MalaCards organs/tissues related to Viral Pneumonia:

40
Lung, Bone, Heart, Skin, Kidney, Liver, Bone Marrow

Publications for Viral Pneumonia

Articles related to Viral Pneumonia:

(show top 50) (show all 1507)
# Title Authors PMID Year
1
MANet: A two-stage deep learning method for classification of COVID-19 from Chest X-ray images. 61
33753962 2021
2
Automated Detection of Covid-19 from Chest X-ray scans using an optimized CNN architecture. 61
33649705 2021
3
Therapeutic options for COVID-19: a quick review. 61
33427110 2021
4
COVIDetection-Net: A tailored COVID-19 detection from chest radiography images using deep learning. 61
33551492 2021
5
Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association. 61
33795490 2021
6
Laparoscopic Surgery and the debate on its safety during COVID-19 pandemic: A systematic review of recommendations. 61
32855070 2021
7
Hybrid ensemble model for differential diagnosis between COVID-19 and common viral pneumonia by chest X-ray radiograph. 61
33610001 2021
8
Thromboembolic complications of COVID-19. 61
33159219 2021
9
Medical progress: Stem cells as a new therapeutic strategy for COVID-19. 61
33601098 2021
10
Surgical tracheostomy in a cohort of COVID-19 patients. 61
33666682 2021
11
Disseminated Varicella-zoster Virus Infection Causing Fatal Pneumonia in an Immunocompromised Patient with Chronic Interstitial Pneumonia. 61
33162474 2021
12
SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters. 61
33574037 2021
13
Simple equations to predict the effects of veno-venous ECMO in decompensated Eisenmenger syndrome. 61
33630406 2021
14
Hypercapnia selectively modulates LPS-induced changes in innate immune and DNA replication-related gene transcription in the macrophage. 61
33633835 2021
15
Psychiatric and Nonpsychiatric Comorbidities Among Children With ADHD: An Exploratory Analysis of Nationwide Claims Data in Germany. 61
31364481 2021
16
Otolaryngological symptoms in COVID-19. 61
32875391 2021
17
Factors Associated with Worsening Oxygenation in Patients with Non-severe COVID-19 Pneumonia. 61
33401345 2021
18
Corrected Minute Ventilation Is Associated With Mortality in ARDS Caused by COVID-19. 61
33293365 2021
19
Imaging features of COVID-19: What we can learn from SARS and MERS (Review). 61
33732329 2021
20
A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression. 61
33246355 2021
21
COVID-19 pneumonia: computer-aided quantification of healthy lung parenchyma, emphysema, ground glass and consolidation on chest computed tomography (CT). 61
33206301 2021
22
Dose simulations of an early 20th century kilovoltage pneumonia radiotherapy technique performed with a modern fluoroscope. 61
32958360 2021
23
Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients. 61
32797641 2021
24
Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. 61
33418248 2021
25
Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods. 61
33520684 2021
26
Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms. 61
33476761 2021
27
Diagnostic yield of a bronchoalveolar lavage fluid galactomannan assay in patients with negative serum galactomannan results suspected to have invasive pulmonary aspergillosis. 61
33740824 2021
28
Characteristics of viral pneumonia in the COVID-19 era: an update. 61
33782861 2021
29
Late Outcomes After Pulmonary Arterial Reconstruction in Patients With Arterial Tortuosity Syndrome. 61
33811889 2021
30
Epidemiology of asymptomatic and symptomatic Coronavirus Disease 2019 confirmed cases in the Emirate of Abu Dhabi, United Arab Emirates: Observational study. 61
33761710 2021
31
Hypoxia-inducible factor (HIF): The link between obesity and COVID-19. 61
33521378 2021
32
Aging imparts cell-autonomous dysfunction to regulatory T cells during recovery from influenza pneumonia. 61
33600379 2021
33
Pneumonia in infancy and risk for asthma - the role of familial confounding and pneumococcal vaccination. 61
33727032 2021
34
[COVID-19 in children: SARS-CoV-2-related inflammatory multisystem syndrome mimicking Kawasaki disease]. 61
33753947 2021
35
FLANNEL (Focal Loss bAsed Neural Network EnsembLe) for COVID-19 detection. 61
33125051 2021
36
Surgical Revascularization With Cardiopulmonary Bypass on a Patient With Severe COVID-19. 61
33054611 2021
37
An evaluation of chest computed tomography and hemogram data in patients with COVID-19: The importance of the thymus. 61
33641314 2021
38
Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19. 61
33585705 2021
39
The prognostic value of C-reactive protein for children with pneumonia. 61
32969099 2021
40
An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor. 61
33685364 2021
41
Multi-classifier-based identification of COVID-19 from chest computed tomography using generalizable and interpretable radiomics features. 61
33497881 2021
42
The prediction of the lifetime of the new coronavirus in the USA using mathematical models. 61
33716562 2021
43
Qingfei oral liquid inhibited autophagy to alleviate inflammation via mTOR signaling pathway in RSV-infected asthmatic mice. 61
33706133 2021
44
SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2. 61
33774672 2021
45
Sociodemographic, Clinical Characteristics, and Outcomes of Influenza Pneumonia Patients Admitted in a Tertiary Care Hospital in Karachi, Pakistan: Findings from a Cross-sectional Study. 61
33775024 2021
46
Application of Bayesian phylogenetic inference modelling for evolutionary genetic analysis and dynamic changes in 2019-nCoV. 61
32743639 2021
47
Pneumonia After Bacterial or Viral Infection Preceded or Followed by Radiation Exposure: A Reanalysis of Older Radiobiologic Data and Implications for Low-Dose Radiation Therapy for Coronavirus Disease 2019 Pneumonia. 61
33011212 2021
48
Prognostic Value of Procalcitonin and C-Reactive Protein in 1608 Critically Ill Patients with Severe Influenza Pneumonia. 61
33810263 2021
49
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. 61
33734043 2021
50
Vitamin C and corticosteroids in viral pneumonia. 61
33687858 2021

Variations for Viral Pneumonia

Expression for Viral Pneumonia

Search GEO for disease gene expression data for Viral Pneumonia.

Pathways for Viral Pneumonia

Pathways related to Viral Pneumonia according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 TNF IL6 IL17A IL10 IFNB1 IFITM3
2
Show member pathways
13.83 TNF IL6 IL17A IL10 CXCL8 CXCL10
3
Show member pathways
13.71 TNF IL6 IL17A IL10 IFNB1 CXCL8
4
Show member pathways
13.55 TNF IL6 IL17A IL10 IFNB1 CXCL8
5
Show member pathways
13.46 TNF IL6 IL17A IL10 CXCL8 CXCL10
6
Show member pathways
13.34 TNF IL6 IL17A IL10 CXCL8 CXCL10
7
Show member pathways
13.28 TNF IL6 IL17A IL10 IFNB1 IFITM3
8
Show member pathways
13.23 TNF SFTPD IL6 IL10 IFNB1 DDX58
9
Show member pathways
12.97 TNF IL6 IFNB1 CXCL8 CD4 CCL5
10
Show member pathways
12.9 TNF IL6 IL17A IL10 CXCL8 CD8A
11
Show member pathways
12.87 TNF IL6 IFNB1 DDX58 CXCL8 CXCL10
12 12.81 TNF IL6 IFNB1 DDX58 CCL5
13
Show member pathways
12.66 TNF IL6 IL17A IL10 CD8A CD4
14
Show member pathways
12.63 TNF IL6 IL17A IL10 CD4
15
Show member pathways
12.62 TNF IL6 IL17A IL10 CD4
16
Show member pathways
12.59 IL6 IFNB1 DDX58 CXCL10 CCL5
17 12.59 TNF IL17A IL10 DDX58 CXCL10 CD8A
18
Show member pathways
12.58 TNF IFNB1 DDX58 CXCL8 CXCL10
19 12.41 TNF IFNB1 CXCL8 CCL5
20
Show member pathways
12.39 TNF IL6 IL17A CXCL8 CXCL10
21
Show member pathways
12.34 TNF IL6 CRP CCL5
22 12.31 TNF IL6 IFNB1 CXCL8 CCL5
23
Show member pathways
12.31 TNF IL6 IL17A IL10 IFNB1 IFITM3
24 12.3 TNF IL6 IL10 IFNB1 CR1
25
Show member pathways
12.28 TNF IL6 IFNB1 CXCL8
26
Show member pathways
12.25 TNF IL6 IL10 CXCL8 CXCL10 CCR6
27 12.21 TNF IL6 IL10 CXCL8
28
Show member pathways
12.19 TNF SFTPD IL6 IFNB1 CXCL8 CXCL10
29 12.07 TNF IL6 IL10 CD8A CD4
30 12.05 TNF IL6 CXCL8 CXCL10
31 12.05 TNF IL6 IL17A IL10 CXCL8
32 12.04 TNF IL6 IFNB1 CXCL10 CCL5
33 11.98 TNF IL6 IL10 CXCL8
34 11.97 TNF IL6 CR1 CD8A CD4
35 11.93 TNF IL6 IL17A CXCL8 CCL5
36 11.84 TNF IL6 IL10 CXCL8
37
Show member pathways
11.8 TNF IL6 IL17A IL10 CD4
38 11.74 TNF IL6 CXCL8 CCL5
39 11.7 TNF IL17A IL10 CD8A CD4 CCR6
40 11.69 TNF IL6 IL10 CR1 CCR6
41
Show member pathways
11.68 TNF IL6 CXCL8
42 11.68 TNF IL6 CXCL8 CR1
43 11.64 TNF IL6 IL10 IFNB1 CXCL8 CD8A
44 11.5 TNF IL6 IL10 CXCL8 CR1
45 11.5 TNF IL6 IL10 IFNB1 CD8A CD4
46 11.43 TNF IL6 IL10
47 11.4 TNF IL6 IL10
48 11.36 TNF IL6 IL17A
49 11.23 TNF IFNB1 CXCL8 CCL5
50 11.12 TNF IL6 IL10 IFNB1 CD4

GO Terms for Viral Pneumonia

Cellular components related to Viral Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNF SFTPD IL6 IL17A IL10 IFNB1
2 extracellular space GO:0005615 9.7 TNF SFTPD IL6 IL17A IL10 IFNB1
3 external side of plasma membrane GO:0009897 9.17 TNF IL17A FCRL6 CXCL10 CD8A CD4

Biological processes related to Viral Pneumonia according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF NR2F2 IL6 IL17A IL10 IFNB1
2 immune system process GO:0002376 10.1 SFTPD IL17A IFITM3 DDX58 CR1 CD8A
3 innate immune response GO:0045087 10.08 SFTPD IL17A IFITM3 DDX58 CRP CR1
4 positive regulation of gene expression GO:0010628 10.07 TNF IL6 DDX58 CXCL8 CRP
5 cell surface receptor signaling pathway GO:0007166 9.98 IFNB1 FCRL6 CXCL10 CD8A CD4
6 chemotaxis GO:0006935 9.91 CXCL8 CXCL10 CCR6 CCL5
7 defense response GO:0006952 9.91 TNF IFNB1 CXCL8 CXCL10
8 defense response to virus GO:0051607 9.89 IL6 IFNB1 IFITM3 DDX58 CXCL10
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.87 TNF IL6 IL10 DDX58
10 defense response to Gram-positive bacterium GO:0050830 9.85 TNF IL6 IL17A CRP
11 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL6 IL10 CXCL8 CXCL10
12 neutrophil chemotaxis GO:0030593 9.84 CXCL8 CXCL10 CCL5
13 regulation of insulin secretion GO:0050796 9.83 TNF IL6 CCL5
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL6 CCL5
15 response to glucocorticoid GO:0051384 9.83 TNF IL6 IL10
16 positive regulation of T cell proliferation GO:0042102 9.82 IL6 CD4 CCL5
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.81 TNF IL6 CCL5
18 positive regulation of interleukin-6 production GO:0032755 9.81 TNF IL6 IL17A DDX58
19 positive regulation of interleukin-8 production GO:0032757 9.8 TNF IL6 DDX58
20 positive regulation of interleukin-1 beta production GO:0032731 9.8 TNF IL6 IL17A
21 inflammatory response GO:0006954 9.8 TNF IL6 IL17A CXCL8 CXCL10 CRP
22 chemokine-mediated signaling pathway GO:0070098 9.78 CXCL8 CXCL10 CCR6 CCL5
23 negative regulation of T cell proliferation GO:0042130 9.77 SFTPD IL10 CR1
24 humoral immune response GO:0006959 9.73 TNF IL6 IFNB1 CCR6
25 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.7 TNF IL6 IL17A
26 response to molecule of bacterial origin GO:0002237 9.67 IL10 CXCL8
27 negative regulation of viral genome replication GO:0045071 9.67 TNF IFNB1 IFITM3 CCL5
28 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
29 vascular endothelial growth factor production GO:0010573 9.63 TNF IL6
30 response to virus GO:0009615 9.63 TNF IFNB1 IFITM3 DDX58 CXCL10 CCL5
31 negative regulation of cytokine production involved in immune response GO:0002719 9.62 TNF IL10
32 positive regulation of JAK-STAT cascade GO:0046427 9.62 TNF IL6 IL10 CCL5
33 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL6 IL17A IL10 IFNB1 CXCL8
34 positive regulation of cellular biosynthetic process GO:0031328 9.58 CXCL8 CCL5
35 negative regulation of lipid storage GO:0010888 9.58 TNF IL6 CRP
36 immune response GO:0006955 9.36 TNF IL6 IL17A IL10 IFITM3 CXCL8

Molecular functions related to Viral Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TNF SFTPD NSMCE3 NR2F2 IL6 IL17A
2 virus receptor activity GO:0001618 9.5 CR1 CD4 ACE2
3 chemokine activity GO:0008009 9.33 CXCL8 CXCL10 CCL5
4 MHC class II protein binding GO:0042289 9.26 FCRL6 CD4
5 cytokine activity GO:0005125 9.23 TNF IL6 IL17A IL10 IFNB1 CXCL8

Sources for Viral Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....